Flow Cytometry Lab

Our Flow Cytometry Lab

The Spectrum Health Flow Cytometry Laboratory is the only hospital-based clinical flow cytometry lab in West Michigan and serves hospitals across the U.S. and Canada. Testing is performed annually on more than 6,200 specimens, including peripheral blood, bone marrow, tissue samples and body fluids. Our laboratory performs multicolor immunophenotyping analysis on state-of-the-art flow cytometers. 

We offer a variety of tests, including diagnostic testing for lymphoma, acute or chronic leukemia, plasma cell neoplasms and myelodysplastic syndromes. Our Flow Cytometry Lab is able to provide physicians with preliminary results for a new leukemia in less than three hours, which allows the physician to immediately begin a targeted treatment based upon the specific type of leukemia. In addition, preliminary cytogenetic testing results are available within 24 hours and can be correlated with the flow cytometry result to provide the physician with a clearer understanding of the specific leukemia or lymphoma present. 

Clinical testing includes: 
  • Leukemia diagnosis 
  • Lymphoma diagnosis 
  • Monitoring of patients with leukemia and lymphoma 
  • Minimal residual disease assessment 
  • Neuroblastoma testing 
  • Paroxysmal nocturnal hemoglobinuria (PNH) 
  • HLA-B27 screen 
  • Hemoglobin F for fetal cells 
  • DNA ploidy analysis for neoplasms 
  • Immunologic testing 
  • Immune competency panels (B cell and T cell subset testing) 
  • Oxidative burst assay for chronic granulomatous disease (CGD) 
  • Leukocyte adhesion deficiency (LAD) 
The Flow Cytometry Laboratory is currently participating in the groundbreaking multiyear Multiple Myeloma Research Foundation COMMPASS research study. We are also running a two-year-long validation study to be approved for minimal residual disease testing in B lymphoblastic leukemia (B cell ALL) for patients enrolled in COG trials. 

Neuroblastoma testing is performed by the Flow Cytometry Laboratory and used to diagnose, stage and monitor children with neuroblastoma. We are also performing testing for the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), which consists of a group of 25 universities and children’s hospitals. The NMTRC offers a nationwide network of childhood cancer clinical trials and is headquartered here at Spectrum Health Helen DeVos Children’s Hospital.